violacein has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ay Sal, F; Belduz, AO; Bozdal, G; Canakcı, S; Ceylan, E; Dogancı, MA; Guler, HI; Katı, H; Yaylı, N | 1 |
1 other study(ies) available for violacein and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Investigation of potential inhibitor properties of violacein against HIV-1 RT and CoV-2 Spike RBD:ACE-2.
Topics: Angiotensin-Converting Enzyme 2; COVID-19; HIV-1; Indoles; Peptidyl-Dipeptidase A; Phylogeny; Protein Binding; RNA, Ribosomal, 16S; SARS-CoV-2; Spike Glycoprotein, Coronavirus | 2022 |